We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
immatics Wins 2012 TiE50 Award
News

immatics Wins 2012 TiE50 Award

immatics Wins 2012 TiE50 Award
News

immatics Wins 2012 TiE50 Award

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "immatics Wins 2012 TiE50 Award"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

immatics biotechnologies GmbH has announced that it has been named a 2012 TiE50 winner.

These prestigious awards recognize entrepreneurship, innovation and management excellence within the life sciences, software, internet, mobile and energy sectors.

immatics was chosen from more than 2,100 technology start-ups, judged by a panel of industry experts ranging from venture capital to entrepreneurs.

The awards were showcased on 18-19 May 2012 at 2012 TiEcon, the world’s largest convention dedicated to entrepreneurs, in Santa Clara, California.

Paul Higham, immatics’ CEO, said: “The TiE50 Award acknowledges immatics’ significant progress in developing innovative therapies for difficult to treat cancers. The positive phase 2 results that we have reported with IMA901 for renal cell carcinoma and IMA910 for colorectal cancer highlight the potential for our multi-peptide cancer vaccines to play an important role in improving the treatment of cancer. The judges were impressed with the rapid development of our vaccines, particularly the fast transition of IMA901 into the phase 3 study. We expect to continue this good progress and to create products with meaningful benefits for patients.”

Advertisement